Exosomes in Aesthetic Medicine: Between Scientific Potential, Marketing, and Safety

Just a few years ago, exosomes were discussed mainly in the context of cell biology and regenerative medicine. Today, the term is appearing increasingly often in descriptions of aesthetic procedures, professional serums, recovery protocols after laser treatments, microneedling therapy, and home-care products.

Exosomes are credited with the ability to stimulate skin renewal, improve firmness, reduce the appearance of wrinkles, accelerate recovery after procedures, even out skin tone, and even support hair growth. Some of these areas do have a scientific basis. However, there is a considerable distance between a promising laboratory study, a small clinical trial, and a finished commercial product.

The main issue is not that exosomes do not work. It is that products sold under the same name may differ greatly in origin, composition, purity, concentration, and biological activity. That is why judging them solely by the word “exosomes” on the label is not enough.

In the professional community, two opposing approaches to this technology have already emerged. Supporters call exosomes the next stage in the development of regenerative aesthetics. Skeptics point to insufficient standardization, the limited number of large clinical studies, and excessive marketing activity. In reality, both positions are partly justified: the biological potential of exosomes is substantial, but the quality of evidence and the properties of specific commercial preparations can vary significantly.

What exosomes are and why aesthetic medicine became interested in them

The cells of the human body do not exist in isolation. They constantly exchange signals that help coordinate inflammation, tissue repair, immune responses, growth, aging, and cell death.

One way this communication occurs is through the release of extracellular vesicles — microscopic particles surrounded by a lipid membrane. They may contain proteins, lipids, enzymes, RNA fragments, and other biologically active molecules.

Exosomes are one subtype of extracellular vesicles. They are formed inside the cell and then released into the intercellular space. When these vesicles reach other cells, they can transmit a specific set of molecular signals to them.

In simplified terms, an exosome can be compared to a small protected container in which one cell sends information to another. However, the contents of this container are not universal. They depend on the type of cell, its age, condition, culture environment, the presence of inflammation, stress, oxygen deprivation, and many other factors.

This is why exosomes from different sources cannot be considered interchangeable. Particles obtained from cultures of mesenchymal cells, fibroblasts, keratinocytes, platelets, plant raw materials, or microbial cultures may have fundamentally different compositions and potential effects.

In addition, not every extracellular vesicle can automatically be called an exosome. In scientific practice, this term implies not only a certain particle size but also a confirmed mechanism of formation inside the cell. Laboratory methods are used to characterize the material by determining particle size, concentration, structure, membrane integrity, the presence of characteristic protein markers, and the purity of the obtained fraction.

“The nomenclature section presents the diversity of extracellular vesicles and the need to avoid incorrect use of the term ‘exosome’.”

International guidelines for extracellular vesicle research recommend using the word “exosomes” with caution if their intracellular origin has not been reliably confirmed. In many cases, it is more scientifically accurate to refer to extracellular vesicles, small extracellular vesicles, or a fraction enriched with them.

For aesthetic medicine, this field has become especially interesting because of the complex nature of skin aging. Age-related changes are not associated only with a decrease in collagen. Over time, fibroblast function changes, intercellular communication deteriorates, damage caused by ultraviolet radiation and oxidative stress accumulates, chronic low-grade inflammation intensifies, and tissue repair becomes slower.

Extracellular vesicles have attracted researchers’ attention because of their ability to transport molecules that may influence several processes at once:

• fibroblast activity and migration;
• synthesis of extracellular matrix components;
• formation of collagen and elastin;
• keratinocyte behavior;
• the inflammatory response;
• formation of new blood vessels;
• healing of damaged tissues;
• oxidative stress;
• melanocyte function;
• activity of hair follicle cells.

This is the fundamental difference between the exosome-based approach and the use of a single active ingredient. In theory, a vesicle can carry a complex of interconnected signals rather than one molecule with a narrow action. At the same time, this complexity makes control more difficult: together with potentially beneficial molecules, the fraction may contain undesirable or insufficiently studied components.

Exosomes do not have a universal function of their own. They are carriers of information, and the nature of that information is determined by the cell that produced them and the conditions in which it existed. Therefore, it is more accurate to speak not about the effect of exosomes in general, but about the properties of specific extracellular vesicles obtained from a particular source using a particular manufacturing protocol.

What may actually be in a product labeled “exosomes”

One of the main reasons for confusion in the market is that the term “exosomes” is applied to products that differ substantially from one another. A commercial preparation may contain:

• purified or partially purified extracellular vesicles;
• the culture medium in which cells were grown;
• a secretome — the collection of substances released by cells into their surrounding environment;
• growth factors and signaling proteins without confirmed exosomes;
• liposomes or artificial vesicles that mimic the structure of natural particles;
• plant nanoparticles referred to in promotional materials as plant exosomes;
• a mixture of several of the components listed above.

These categories are not necessarily ineffective or unsuitable for aesthetic use. Secretomes, growth factors, peptides, liposomes, and plant nanoparticles can also have biological activity. However, they are not identical to one another and require separate evidence. The presence of beneficial proteins or growth factors does not confirm the presence of functionally active exosomes.

The origin of the material is highly important. A significant portion of scientific research concerns vesicles obtained from cultures of mesenchymal stromal cells. The source of these cells may be adipose tissue, bone marrow, umbilical cord, placenta, and other tissues.

They are studied because of their potential ability to modulate inflammation, support regeneration, and affect connective tissue cells. However, biological origin requires strict control of donor material, manufacturing conditions, sterility, purification, and traceability of every batch.

Fibroblasts, keratinocytes, and other cells associated with the structure of the skin may also be used to obtain extracellular vesicles. Such materials are studied as a potential source of signals close to the natural repair mechanisms of skin tissue.

A separate area is vesicles of platelet origin. Platelets contain a significant number of factors involved in healing, so particles derived from them are considered in the context of regeneration and recovery after injury. At the same time, they should not be automatically equated with platelet-rich plasma. These are related but different biological products with different methods of preparation, purification, and standardization.

So-called plant exosomes or exosome-like nanoparticles are increasingly found in cosmetics. They may be obtained from ginseng, green tea, citrus fruits, grapes, rose, and other botanical raw materials.

These particles represent a separate area of research. However, the results of studies on human cell-derived vesicles cannot automatically be transferred to plant materials. Even if the particles have a similar size and membrane structure, their contents, mechanism of interaction with human cells, and biological activity may differ substantially.

The same applies to synthetic or semi-synthetic delivery systems that imitate certain properties of natural vesicles. They may be more stable, easier to standardize, and may avoid some of the ethical and manufacturing issues associated with materials of human origin. However, calling them natural exosomes is incorrect. They are a separate technological category whose effectiveness must be confirmed by their own studies.

Product labeling should make it possible to understand not only the source of the material but also what exactly was isolated and purified. Terms such as “exosome complex,” “regenerative nanoparticles,” “cellular signals,” or “secretory factors” may sound convincing, but they do not provide sufficient information about the actual composition.

Therefore, when evaluating a preparation, it is important to distinguish three levels. The first is the general scientific potential of extracellular vesicles. The second is the properties of a specific raw material obtained by a specific method. The third is the effectiveness of the finished commercial product after manufacturing, storage, transportation, and use according to the recommended protocol. Evidence at one level cannot automatically replace evidence at another.

What studies show about rejuvenation, skin repair, and hair growth

In laboratory and preclinical studies, extracellular vesicles have shown the ability to influence fibroblasts, collagen synthesis, inflammatory signals, oxidative damage, and tissue repair. Some small human studies also report improvements in skin texture, hydration, elasticity, evenness of tone, and the appearance of fine lines.

Particular attention is drawn to combined protocols in which a product is applied after procedures that temporarily disrupt the skin’s protective barrier. These may include microneedling therapy, fractional laser, radiofrequency microneedling, or another controlled procedure.

In some studies, such combinations showed better results than the device-based procedure alone. However, this does not always make it possible to determine which part of the effect is due specifically to the vesicles, which part is due to other components of the preparation, and which part is due to natural recovery after the procedure itself.

When an exosome-based product is used together with a laser or microneedling therapy, what is actually being studied is the entire combined protocol. The result of such a study does not prove that the same product will provide a similar effect when applied normally to intact skin. Nor does it confirm the effectiveness of another product, even if it has a similar name.

“Exosome-based therapies have demonstrated promising early clinical effects in skin rejuvenation, but the existing evidence is limited by heterogeneity and lack of follow-up.”

This wording accurately reflects the current state of the evidence. The results do look promising, but the clinical base does not yet justify speaking of a universal standard for treatment or rejuvenation.

Most published studies have at least some of the following limitations:

• a small number of participants;
• a short follow-up period;
• differences between vesicle sources;
• different isolation and purification methods;
• different concentrations and application regimens;
• combination with other procedures;
• lack of unified assessment criteria;
• incomplete information about the composition of the finished product;
• lack of direct comparison with placebo;
• limited data on long-term safety;
• possible links between authors and manufacturers of the studied products.

Therefore, current data are more accurately described as encouraging but preliminary. They confirm the need for further research, but they do not yet establish a single reproducible rejuvenation protocol.

The largest body of scientific work is related not only to cosmetic wrinkles but also to tissue repair and wound healing. Preclinical models investigate the effects of vesicles on cell migration, blood vessel formation, remodeling of the extracellular matrix, and regulation of the inflammatory response.

For aesthetic medicine, this is interesting because of the possibility of shortening the period of redness, swelling, and discomfort after laser, radiofrequency, or microneedling procedures. However, the concept of “accelerated recovery” should not turn into a promise of no downtime at all.

After an intensive procedure, the skin goes through natural phases of inflammation, repair, and remodeling. Excessively aggressive suppression of certain elements of the inflammatory response could theoretically also alter the expected outcome. Therefore, the purpose of a recovery product is not simply to remove redness as quickly as possible, but to support a controlled and physiological healing process.

Some studies examine the possible effect of extracellular vesicles on melanogenesis, post-inflammatory pigmentation, and melasma. It is assumed that certain signaling molecules may alter the activity of melanocytes and enzymes involved in melanin production.

However, the composition of vesicles depends on the source cell. One type of particle could theoretically reduce pigment formation, while another could act differently. Therefore, the statement “exosomes brighten the skin” is too general and does not take into account the origin, composition, and concentration of the specific material.

In scar management, interest is related to the potential effect on inflammation, fibroblast activity, and remodeling of collagen fibers. But scars differ in origin, age, depth, and tendency toward pathological growth. Results obtained for atrophic acne scars cannot automatically be applied to hypertrophic or keloid scars.

It is also important to consider that most scar correction protocols are combined. They may include laser treatment, microneedling therapy, subcision, injectable methods, topical products, and home care. If an exosome-based product was used as one component of such a regimen, it may be difficult to isolate its own contribution to the result.

In trichology, extracellular vesicles are studied as a potential way to affect hair follicle cells. Preliminary data suggest increased hair density, improved scalp condition, and support of the active growth phase.

At the same time, hair loss may result from hormonal, autoimmune, deficiency-related, inflammatory, infectious, or genetic causes. No exosome-based product can replace diagnosis of the cause of alopecia. Even a promising stimulating protocol will not correct iron deficiency, thyroid dysfunction, an active inflammatory disease, or a hormonal factor.

It is also necessary to distinguish between a temporary reduction in shedding, an increase in the diameter of existing hair, and the emergence of new active follicles. These are different clinical outcomes that require different assessment methods and sufficiently long follow-up.

Why exosome research does not prove the effectiveness of a specific serum

One of the most common marketing substitutions is the transfer of results from a study of a certain type of vesicle to any product with a similar name.

For example, a scientific study may examine purified vesicles from a specific cell line, obtained according to a defined protocol and used immediately after production. A commercial serum may contain a different source, a different concentration, a different stabilization method, and dozens of additional ingredients.

A study may use material produced under laboratory conditions specifically for the experiment. A product that reaches a clinic or salon undergoes serial manufacturing, filling, storage, international transportation, customs procedures, and distribution chain handling. Each of these stages can affect the integrity and biological activity of vesicles.

To confirm effectiveness, research is needed not only on the general concept or the starting raw material, but on the specific final product:

• at the stated concentration;
• in the finished formula;
• in its commercial packaging;
• after manufacturing and transportation;
• at the end of the stated shelf life;
• with the recommended method of application;
• for a specific procedure and indication;
• in comparison with placebo or a standard protocol;
• with predefined assessment criteria;
• with registration of adverse reactions and a sufficient follow-up period.

References to dozens of laboratory articles do not replace a clinical study of the finished preparation. Likewise, a large number of published papers on exosomes in general does not prove the properties of a product whose manufacturer does not disclose the source, concentration, purification method, and quality control results.

It is also important to pay attention to units of measurement. The advertising phrase “contains billions of exosomes” sounds convincing, but by itself it is not sufficiently informative. It is necessary to know which method was used to count the particles, whether they were distinguished from protein aggregates and other impurities, what volume of the product was tested, and how many intact functional vesicles remain after storage.

A high particle count does not necessarily mean high biological activity. Two fractions with the same declared concentration may differ substantially in origin, molecular content, purity, and ability to interact with skin cells.

Stability is a separate issue. Extracellular vesicles are complex biological structures. Their integrity may be affected by temperature, repeated freezing and thawing, storage duration, formula acidity, enzymes, surfactants, preservatives, light, and mechanical mixing.

Manufacturers use freezing, lyophilization, special buffer solutions, and other stabilization methods. But the mere fact of lyophilization or refrigerated storage does not guarantee that, after reconstitution, the product contains the stated number of intact and biologically active particles.

For professional assessment, it is important to understand:

• at what point the vesicle concentration was measured;
• whether the finished product was tested, not only the fresh raw material;
• whether activity is preserved at the end of shelf life;
• how the product is transported;
• whether it requires an uninterrupted cold chain;
• how long it can remain at room temperature;
• how long it remains usable after opening or reconstitution;
• whether compatibility with the solvent and packaging has been confirmed;
• whether the effect of repeated shaking or drawing the product from the vial has been studied.

The method of application is no less important. Application to intact skin, use after a microneedling or laser procedure, and injection are fundamentally different scenarios.

The stratum corneum limits the penetration of large and complex biological structures. Therefore, for a regular serum, it is necessary to prove that the active components actually reach the target layers of the skin or at least affect its superficial structures. The word “nanosized” alone does not prove sufficient penetration.

Temporary microchannels after a microneedling or laser procedure can increase the penetration of ingredients. At the same time, they raise the requirements for sterility, purity, and composition of the product. A cosmetic product intended only for external application is not necessarily suitable for use on skin with a compromised barrier.

A damaged skin barrier simultaneously facilitates penetration of active substances and increases tissue sensitivity to contaminants, microorganisms, preservatives, fragrances, and other excipients. This is why a professional procedure should not involve automatically delivering through microchannels any serum whose label includes the word “exosomes.”

Injection fundamentally changes the risk profile and regulatory status of the product. The material passes beyond the natural skin barrier, so requirements for sterility, manufacturing, impurity control, and safety evidence become much higher.

The presence of a vial, powder, and solvent does not mean that the product is approved for injection. Likewise, labels such as “professional,” “sterile,” “clinical,” or “for use by physicians” do not confirm official registration specifically for injectable use.

Safety and regulation of exosome-based products

Exosomes are often promoted as a cell-free alternative to cell therapy. They are indeed not living cells and cannot divide like cells. However, this does not make every product automatically safe.

Potential risks include:

• microbial contamination;
• presence of endotoxins;
• mycoplasma contamination;
• residues of culture medium;
• impurities of cellular material;
• residual DNA;
• unpredictable composition of biologically active molecules;
• immune and inflammatory reactions;
• allergy to excipients;
• improper storage;
• disruption of the cold chain;
• use of a non-sterile product on damaged skin;
• injectable use of a product not intended for that purpose.

A separate issue is cell origin and donor control. For materials of human origin, a transparent system of testing, traceability, manufacturing control, and screening for infectious agents is required. It is important to know not only the tissue type but also the conditions under which donor material was obtained, donor selection rules, the method of cell culture, and the composition of the medium.

Animal-derived components, antibiotics, stabilizers, and other substances may be used in production. Even if they are not the main active component, their residues must also be controlled.

Long-term consequences of use have not been sufficiently studied. Exosomes participate in complex signaling processes, and some signals may be undesirable under certain conditions. This does not mean that cosmetic exosomes cause cancer. However, categorical claims of absolute safety also lack a sufficient evidence base.

Additional caution is required for patients with active oncological, autoimmune, infectious, and inflammatory diseases, impaired wound healing, a tendency toward pathological scarring, or unexplained skin lesions. The list of contraindications should be determined not by a promotional presentation, but by the properties of the specific product, the route of administration, and the clinical situation.

Regulatory status depends on the country, the origin of the material, composition, claimed action, and method of use. The same product cannot automatically have the same status in different countries.

In the United States, the Food and Drug Administration emphasizes that exosome products intended to treat diseases or alter the functions of the body may be regulated as drugs and biological products.

“There are currently no FDA-approved exosome products.”

This statement concerns the regulatory status of exosome drug products in the United States and does not mean that any cosmetic with plant or synthetic vesicles is automatically prohibited. At the same time, it directly contradicts promotional claims about “FDA-approved exosome therapy” if the manufacturer cannot name a specific registered product and approved indication.

In the European Union, cosmetics legislation includes the following category in the list of substances prohibited in cosmetic products:

“Cells, tissues or products of human origin.”

For plant, microbial, animal, or artificial vesicles, the legal assessment may differ. However, the product must still comply with requirements for safety, composition, manufacturing, labeling, and substantiation of claimed properties.

It is also necessary to distinguish between cosmetic and medical claims. Promises to “treat,” “regenerate damaged tissues,” “restore hair follicles,” “change the structure of the skin,” or “activate stem cells” may go beyond ordinary cosmetic positioning.

The word “registered” also requires clarification. It may refer to registration of the company, manufacturing site, trademark, cosmetic notification, or distributor, but not necessarily to confirmation of clinical efficacy or approval of a specific procedure.

Likewise, a certificate of analysis for a particular batch does not replace registration documents, and a certificate of compliance with a quality management system does not prove the effectiveness of the finished preparation. Each document answers only a specific question and should not be used as universal confirmation of all product properties.

How a clinic, aesthetic practitioner, and patient should evaluate an exosome-based product

Professional choice should not be limited to a distributor’s presentation, before-and-after photos, and general references to scientific articles. Before including a product in a protocol, it is worth obtaining answers to specific questions.

1. What exactly does the preparation contain? Exosomes, other extracellular vesicles, a secretome, culture medium, growth factors, liposomes, or a combination of these.
2. What is the origin of the material? Cell type, species, tissue, donor-derived, plant, microbial, or synthetic material.
3. How has the presence of vesicles been confirmed? Data are needed on particle size, concentration, markers, purity, and integrity.
4. What is the concentration? Units of measurement, counting method, and acceptable batch-to-batch range are required.
5. Has the final product been studied? Data only on the starting raw material do not confirm the properties of the finished formula.
6. How is safety controlled? Sterility, endotoxins, mycoplasma, viral safety, residual DNA, and other impurities depending on origin.
7. What are the storage conditions? Temperature, transportation, cold chain, shelf life after opening or reconstitution.
8. What method of use is the product intended for? Intact skin, post-procedure application, or injection.
9. What clinical studies have been conducted? Number of participants, control group, follow-up duration, assessment criteria, and adverse reactions.
10. What is the legal status? Documents are needed specifically for the country where the product is used.
11. Can the specific batch be traced? The packaging should show the batch number, manufacturing date, expiry date, and storage conditions.
12. Who is responsible for the product? The manufacturer, official importer, and distributor should be clearly identified.

A manufacturer claiming to offer a high-tech biological product should be prepared to provide much more information than a standard advertising brochure. A lack of transparent data cannot be compensated for by complex terminology, impressive laboratory photographs, or the brand’s participation in professional exhibitions.

Particular caution is needed with claims that do not include specific parameters. The following statements should raise concern:

• “suitable for everyone”;
• “has no risks whatsoever”;
• “replaces injections, lasers, and surgery”;
• “rejuvenates at the cellular level” without explaining the mechanism;
• “contains billions of exosomes” without a measurement method;
• “approved worldwide” without the name of the regulator and document;
• “creates new skin cells”;
• “completely restores collagen”;
• “treats hair loss regardless of the cause”;
• “results proven by studies” when a different product was studied;
• “contains no cells, therefore absolutely safe”;
• “certified” if it is not explained exactly which certificate is meant.

The more complex the technology, the more specific the information should be. A large number of scientific terms should not replace data on composition, manufacturing, stability, method of application, and clinical results.

Before-and-after photos also require critical evaluation. Skin appearance can be influenced by lighting, shooting angle, facial expression, makeup, hydration, camera settings, and other procedures performed at the same time. Without standardized photography and a description of the full protocol, such materials remain promotional illustrations rather than clinical evidence.

Before a procedure, it is important for the patient or consumer to clarify not only its cost and expected result:

• the full name of the product and its manufacturer;
• the source of the claimed exosomes;
• whether the preparation is intended specifically for the proposed method of use;
• whether the integrity of the skin will be disrupted;
• who will perform the procedure and what qualifications they have;
• possible adverse reactions;
• contraindications;
• whether the original packaging, batch number, and expiry date can be seen;
• how the product was stored before the procedure;
• what to do in the event of an adverse reaction;
• which alternative methods have better-confirmed effectiveness.

Refusal to provide the name of the product, the origin of the material, instructions, or documents is a sufficient reason to postpone the procedure. The patient has the right to know what substance is being applied to damaged skin or is planned for injection.

A realistic discussion of the outcome is equally important. Even a high-quality and well-studied product cannot guarantee the same response in all patients. Results are influenced by age, phototype, skin condition, the presence of chronic diseases, lifestyle, smoking, ultraviolet exposure, home care, and combination with other procedures.

Exosome-based preparations should not replace methods with a more established evidence base simply because the technology is new. In some cases, photoprotection, retinoids, control of inflammatory diseases, laser methods, chemical peels, injectable products with a defined composition, or treatment of the underlying cause of hair loss may remain the more rational choice.

Scientific interest in extracellular vesicles is entirely justified. They participate in intercellular communication, can carry complex sets of biological signals, and show potential in regeneration, wound healing, skin repair, and hair follicle research.

At the same time, the word “exosomes” currently runs far ahead of the level of market standardization. It may conceal different sources, technologies, and formulas — from well-characterized extracellular vesicles to secretomes, plant particles, synthetic delivery systems, and ordinary cosmetic complexes with growth factors.

Therefore, a professional approach is neither unconditional enthusiasm for the new technology nor its complete rejection. It is necessary to evaluate the specific product: its origin, characterization, purity, stability, method of application, clinical evidence, and legal status.

Exosomes may become an important part of future regenerative aesthetics. But the path from a promising biological platform to a reproducible, safe, and evidence-based protocol is not yet complete.

This material is for informational purposes only and does not replace medical consultation, individual diagnosis, or verification of the regulatory status of a specific product.